<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2024-6025</article-id><article-id custom-type="edn" pub-id-type="custom">FIDYSH</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-6025</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПРОГНОЗИРОВАНИЕ И ДИАГНОСТИКА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PROGNOSIS AND DIAGNOSTICS</subject></subj-group></article-categories><title-group><article-title>Ассоциация новых биомаркеров системного воспаления с развитием атеросклероза и его выраженностью</article-title><trans-title-group xml:lang="en"><trans-title>Association of novel biomarkers of systemic inflammation with atherosclerosis and its severity</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8931-0376</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шварц</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Shvarts</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шварц Владимир Александрович — д. м. н., в. н. с. отделения хирургического лечения интерактивной патологии, профессор кафедры сердечно-сосудистой хирургии с курсом аритмологии и клинической электрофизиологии.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">shvartz.va@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7489-9798</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Талибова</surname><given-names>С. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Talibova</surname><given-names>S. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Талибова Саялы М. — аспирант, врач-кардиолог.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">shvartz.va@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6037-1327</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сокольская</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sokolskaya</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сокольская Мария А. — к. м. н., н. с. отделения хирургического лечения интерактивной патологии, доцент кафедры кардиологии, функциональной и ультразвуковой диагностики с курсом детской кардиологии.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">shvartz.va@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6830-0411</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Испирян</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Ispiryan</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Испирян Артак Ю. — к. м. н., с. н. с. отделения хирургического лечения интерактивной патологии, кардиолог.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">shvartz.va@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8638-7327</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шварц</surname><given-names>Е. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Shvarts</surname><given-names>E. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шварц Елена Н. — м. н. с. центра координации фундаментальной научной деятельности.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">shvartz.va@ya.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0001-0693</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петросян</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrosyan</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Петросян Андрей Д. — к. м. н., сердечно-сосудистый хирург.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">shvartz.va@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5638-3723</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мерзляков</surname><given-names>В. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Merzlyakov</surname><given-names>V. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мерзляков Вадим Ю. — д. м. н., зав. отделением хирургического лечения ИБС и малоинвазивной коронарной хирургии, профессор кафедры сердечно-сосудистой хирургии с курсом аритмологии и клинической электрофизиологии.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">shvartz.va@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4463-0755</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Скопин</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Skopin</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Скопин Антон И. — к. м. н., сердечно-сосудистый хирург отделения хирургического лечения ИБС и малоинвазивной коронарной хирургии.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">shvartz.va@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0942-2931</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Донаканян</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Donakanyan</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Донаканян Сергей А. — д. м. н., зав. отделением хирургического лечения интерактивной патологии, профессор кафедры сердечно-сосудистой хирургии с курсом аритмологии и клинической электрофизиологии, сердечно-сосудистый хирург.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">shvartz.va@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ НМИЦ ССХ им. А.Н. Бакулева Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bakulev National Medical Research Center for Cardiovascular Surgery</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ Национальный медицинский исследовательский центр терапии и профилактической медицины Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>12</day><month>08</month><year>2024</year></pub-date><volume>29</volume><issue>8</issue><fpage>6025</fpage><lpage>6025</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шварц В.А., Талибова С.М., Сокольская М.А., Испирян А.Ю., Шварц Е.Н., Петросян А.Д., Мерзляков В.Ю., Скопин А.И., Донаканян С.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Шварц В.А., Талибова С.М., Сокольская М.А., Испирян А.Ю., Шварц Е.Н., Петросян А.Д., Мерзляков В.Ю., Скопин А.И., Донаканян С.А.</copyright-holder><copyright-holder xml:lang="en">Shvarts V.A., Talibova S.M., Sokolskaya M.A., Ispiryan A.Y., Shvarts E.N., Petrosyan A.D., Merzlyakov V.Y., Skopin A.I., Donakanyan S.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/6025">https://russjcardiol.elpub.ru/jour/article/view/6025</self-uri><abstract><sec><title>Цель</title><p>Цель. Сравнить уровни новых биомаркеров системного воспаления у пациентов с атеросклерозом и без него, а также между группами пациентов с различной его выраженностью.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Были включены пациенты с подозрением на ишемическую болезнь сердца, которым выполнена селективная коронароангиография. Включен в анализ 901 пациент, средний возраст 61±10 лет, 60% (n=549) мужчин. Пациенты были разделены на две группы: с атеросклерозом и без него. Для статистической поправки на исходные клинические различия использован метод Propensity Score Matching.</p></sec><sec><title>Результаты</title><p>Результаты. В группе с атеросклерозом показатели индекса системного воспалительного ответа (SIRI), индекса системного воспаления (SII) и совокупного индекса системного воспаления (AISI) были статистически значимо выше, чем у пациентов без атеросклероза: 0,906 (0,632; 1,36) vs 0,745 (0,519; 1,02), p&lt;0,001; 457 (350; 641) vs 425 (313; 547), p=0,005 и 233 (148; 346) vs 179 (121; 263), p&lt;0,001, соответственно. По результатам ROC анализа пороговые значения изучаемых показателей составили: для SIRI &gt;1,05 площадь под кривой (AUC), доверительный интервал (ДИ) 0,615 (0,571-0,658), p&lt;0,001, чувствительность 42,6%, специфичность 77,3%; для SII &gt;368 AUC, ДИ 0,572 (0,528-0,616), p=0,004, чувствительность 72,1%, специфичность 43,4% и для AISI &gt;248 AUC, ДИ 0,604 (0,560-0,647), p&lt;0,001, чувствительность 47,4%, специфичность 71,1%. У SIRI AUC была наибольшей. При сравнении 6 групп по классификации Coronary Artery Surgery Study Class (CASSC) были обнаружены статистически значимые отличия по SIRI и AISI, p&lt;0,001 и p=0,0016, соответственно. Однако эти различия не имели логической закономерности.</p></sec><sec><title>Заключение</title><p>Заключение. Новые маркеры системного воспаления: SIRI, SII и AISI были статистически значимо выше у пациентов с подтвержденным атеросклерозом, чем у пациентов без него. Пороговые уровни, ассоциированные с атеро­склерозом, для SIRI &gt;1,05, для SII &gt;368, для AISI &gt;248.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To compare the levels of novel biomarkers of systemic inflammation in pati­ents with and without atherosclerosis, as well as between groups of patients with atherosclerosis of different severity.</p></sec><sec><title>Material and methods</title><p>Material and methods. Patients with suspected coronary artery disease after selective coronary angiography were included. The analysis included 901 patients with mean age of 61±10 years (men, 60% (n=549)). The patients were divided into two following groups: with and without atherosclerosis. The Propensity Score Matching method was used to adjust for baseline clinical differences.</p></sec><sec><title>Results</title><p>Results. In the group with atherosclerosis, the values of the systemic inflam­mation response index (SIRI), systemic immune-inflammation index (SII) and ag­gregate index of systemic inflammation (AISI) were significantly higher than in patients without atherosclerosis: 0,906 (0,632; 1,36) vs 0,745 (0,519; 1,02), p&lt;0,001; 457 (350; 641) vs 425 (313; 547), p=0,005 and 233 (148; 346) vs 179 (121; 263), p&lt;0,001, respectively. ROC analysis showed the following threshold values of the studied parameters: for SIRI &gt;1,05, area under the curve (AUC) confidence interval (CI) — 0,615 (0,571-0,658), p&lt;0,001, sensitivity — 42,6%, specificity — 77,3%; for SII &gt;368, AUC CI — 0,572 (0,528-0,616), p=0,004, sensitivity — 72,1%, specificity — 43,4%; for AISI &gt;248, AUC CI — 0,604 (0,560-0,647), p&lt;0,001, sensitivity 47,4%, specificity 71,1%. SIRI had the highest AUC. When comparing 6 groups according to the Coronary Artery Surgery Study (CASS) classification, significant differences were found in SIRI and AISI, p&lt;0,001 and p=0,0016, respectively. However, these differences did not have a logical pattern.</p></sec><sec><title>Conclusion</title><p>Conclusion. Novel markers of systemic inflammation (SIRI, SII and AISI) were significantly higher in patients with confirmed atherosclerosis than in patients without it. There are following threshold levels associated with atherosclerosis: for SIRI &gt;1,05, for SII &gt;368, for AISI &gt;248.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>атеросклероз</kwd><kwd>новые биомаркеры воспаления</kwd><kwd>индекс системного воспаления (SII)</kwd><kwd>индекс системного воспалительного ответа (SIRI)</kwd><kwd>совокупный индекс системного воспаления (AISI)</kwd></kwd-group><kwd-group xml:lang="en"><kwd>atherosclerosis</kwd><kwd>novel inflammatory biomarkers</kwd><kwd>systemic immune-inflammation index (SII)</kwd><kwd>systemic inflammation response index (SIRI)</kwd><kwd>aggregate index of systemic inflammation (AISI)</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О. М., Бубнова М. Г., Самородская И. В. и др. Динамика показателей смертности от острых форм ишемической болезни сердца в Российской Федерации за период с 2015 по 2019 годы. Российский кардиологический журнал. 2021;26(5):4441. doi:10.15829/1560-4071-2021-4441.</mixed-citation><mixed-citation xml:lang="en">Drapkina OM, Bubnova MG, Samorodskaya IV, et al. Changes in mortality rates from acute types of coronary artery disease in Russia for the period from 2015 to 2019. Rus­sian Journal of Cardiology. 2021;26(5):4441. (In Russ.) doi:10.15829/1560-4071-2021-4441.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Булаева Н. И., Голухова Е. З. Эндотелиальная дисфункция и оксидативный стресс: роль в развитии кардиоваскулярной патологии. Креативная кардиология. 2013;1:14-22.</mixed-citation><mixed-citation xml:lang="en">Bulaeva NI, Golukhova EZ. Endothelial dysfunction and oxidant stress: the role in car­diovascular pathology. Kreativnaja kardiologija. 2013;1:14-22. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ежов М. В., Кухарчук В. В., Сергиенко И. В. и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. doi:10.15829/1560-4071-2023-5471.</mixed-citation><mixed-citation xml:lang="en">Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.) doi:10.15829/1560-4071-2023-5471.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17(11):1410-22. doi:10.1038/nm.2538.</mixed-citation><mixed-citation xml:lang="en">Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17(11):1410-22. doi:10.1038/nm.2538.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Москаленко С. А., Шувалова Ю. А., Каминный А. И. Роль системы интерлейкина-6 в развитии атеросклероза. Атеросклероз и дислипидемии. 2020;2(39):5-11. doi:10.34687/2219-8202.JAD.2020.02.0001.</mixed-citation><mixed-citation xml:lang="en">Moskalenko SA, Shuvalova YA, Kaminnyi AI. The role of the Interleukin-6 system in the development of atherosclerosis. The Journal of Atherosclerosis and Dyslipidemias. 2020;2(39):5-11. (In Russ.) doi:10.34687/2219-8202.JAD.2020.02.0001.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158-67. doi:10.1002/cncr.3005.</mixed-citation><mixed-citation xml:lang="en">Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158-67. doi:10.1002/cncr.3005.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Geng Y, Zhu D, Wu C, et al. A novel systemic inflammation response index (SIRI) for pre­dicting postoperative survival of patients with esophageal squamous cell carcinoma. Int Immunopharmacol. 2018;65:503-10. doi:10.1016/j.intimp.2018.10.002.</mixed-citation><mixed-citation xml:lang="en">Geng Y, Zhu D, Wu C, et al. A novel systemic inflammation response index (SIRI) for pre­dicting postoperative survival of patients with esophageal squamous cell carcinoma. Int Immunopharmacol. 2018;65:503-10. doi:10.1016/j.intimp.2018.10.002.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Li J, He D, Yu J, et al. Dynamic Status of SII and SIRI Alters the Risk of Cardiovascular Diseases: Evidence from Kailuan Cohort Study. J Inflamm Res. 2022;15:5945-57. doi:10.2147/JIR.S378309.</mixed-citation><mixed-citation xml:lang="en">Li J, He D, Yu J, et al. Dynamic Status of SII and SIRI Alters the Risk of Cardiovascular Diseases: Evidence from Kailuan Cohort Study. J Inflamm Res. 2022;15:5945-57. doi:10.2147/JIR.S378309.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Jin Z, Wu Q, Chen S, et al. The Associations of Two Novel Inflammation Indexes, SII and SIRI with the Risks for Cardiovascular Diseases and All-Cause Mortality: A Ten-Year Follow-Up Study in 85,154 Individuals. J Inflamm Res. 2021;14:131-40. doi:10.2147/JIR.S283835.</mixed-citation><mixed-citation xml:lang="en">Jin Z, Wu Q, Chen S, et al. The Associations of Two Novel Inflammation Indexes, SII and SIRI with the Risks for Cardiovascular Diseases and All-Cause Mortality: A Ten-Year Follow-Up Study in 85,154 Individuals. J Inflamm Res. 2021;14:131-40. doi:10.2147/JIR.S283835.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wheeler JG, Mussolino ME, Gillum RF, et al. Associations between differential leucocyte count and incident coronary heart disease: 1764 incident cases from seven prospective studies of 30,374 individuals. Eur Heart J. 2004;25(15):1287-92. doi:10.1016/j.ehj.2004.05.002.</mixed-citation><mixed-citation xml:lang="en">Wheeler JG, Mussolino ME, Gillum RF, et al. Associations between differential leucocyte count and incident coronary heart disease: 1764 incident cases from seven prospective studies of 30,374 individuals. Eur Heart J. 2004;25(15):1287-92. doi:10.1016/j.ehj.2004.05.002.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Joshi A, Bhambhani A, Barure R, et al. Neutrophil-lymphocyte ratio and platelet-lympho­cyte ratio as markers of stable ischemic heart disease in diabetic patients: An observa­tional study. Medicine. 2023;102(5):e32735. doi:10.1097/MD.0000000000032735.</mixed-citation><mixed-citation xml:lang="en">Joshi A, Bhambhani A, Barure R, et al. Neutrophil-lymphocyte ratio and platelet-lympho­cyte ratio as markers of stable ischemic heart disease in diabetic patients: An observa­tional study. Medicine. 2023;102(5):e32735. doi:10.1097/MD.0000000000032735.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Yang YL, Wu CH, Hsu PF, et al. Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. Eur J Clin Invest. 2020;50(5):e13230. doi:10.1111/eci.13230.</mixed-citation><mixed-citation xml:lang="en">Yang YL, Wu CH, Hsu PF, et al. Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. Eur J Clin Invest. 2020;50(5):e13230. doi:10.1111/eci.13230.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Li Q, Ma X, Shao Q, et al. Prognostic Impact of Multiple Lymphocyte-Based Inflammatory Indices in Acute Coronary Syndrome Patients. Front Cardiovasc Med. 2022;9:811790. doi:10.3389/fcvm.2022.811790.</mixed-citation><mixed-citation xml:lang="en">Li Q, Ma X, Shao Q, et al. Prognostic Impact of Multiple Lymphocyte-Based Inflammatory Indices in Acute Coronary Syndrome Patients. Front Cardiovasc Med. 2022;9:811790. doi:10.3389/fcvm.2022.811790.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Xia Y, Xia C, Wu L, et al. Systemic Immune Inflammation Index (SII), System Inflammation Response Index (SIRI) and Risk of All-Cause Mortality and Cardiovascular Mortality: A 20-Year Follow-Up Cohort Study of 42,875 US Adults. J Clin Med. 2023;12(3):1128. doi:10.3390/jcm12031128.</mixed-citation><mixed-citation xml:lang="en">Xia Y, Xia C, Wu L, et al. Systemic Immune Inflammation Index (SII), System Inflammation Response Index (SIRI) and Risk of All-Cause Mortality and Cardiovascular Mortality: A 20-Year Follow-Up Cohort Study of 42,875 US Adults. J Clin Med. 2023;12(3):1128. doi:10.3390/jcm12031128.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Dziedzic EA, Gąsior JS, Tuzimek A, et al. Investigation of the Associations of Novel Inflammatory Biomarkers-Systemic Inflammatory Index (SII) and Systemic Inflammatory Response Index (SIRI)-With the Severity of Coronary Artery Disease and Acute Coronary Syndrome Occurrence. Int J Mol Sci. 2022;23(17):9553. doi:10.3390/ijms23179553.</mixed-citation><mixed-citation xml:lang="en">Dziedzic EA, Gąsior JS, Tuzimek A, et al. Investigation of the Associations of Novel Inflammatory Biomarkers-Systemic Inflammatory Index (SII) and Systemic Inflammatory Response Index (SIRI)-With the Severity of Coronary Artery Disease and Acute Coronary Syndrome Occurrence. Int J Mol Sci. 2022;23(17):9553. doi:10.3390/ijms23179553.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
